Biomolecular Holdings LLC
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2
Ending by 2030
Oct 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Apr 1, 2027The maintenance fee for Hybrid immunoglobulins with moving parts (US 10,428,332) comes due Apr 1, 2027. Unpaid by Oct 1, 2027, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 23, 2026
- Oct 20 US 12,767,733 Dimeric Fusion Proteins
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,428,332 | Hybrid immunoglobulins with moving parts In force · USPTO record | In force | USPTO record | |
| US 12,467,053 | Hybrid immunoglobulins with moving parts In force · USPTO record | In force | USPTO record | |
| US 9,725,503 | Peptide-hinge-free flexible antibody-like molecule In force · USPTO record | In force | USPTO record | |
| US 11,345,745 | Peptide-hinge-free flexible antibody-like molecule In force · USPTO record | In force | USPTO record | |
| US 8,457,745 | Method, system and apparatus for control of pancreatic beta cell function to improve glucose homeostatis and insulin production In force · USPTO record | In force | USPTO record | |
| US 8,768,468 | Device for neuro-physiologic stimulation In force (reinstated) · USPTO record | In force (reinstated) | USPTO record | |
| US 12,371,480 | Peptide-hinge-free flexible antibody-like molecule In force · USPTO record | In force | USPTO record | |
| US 10,968,263 | Affinity Support and Method for Trapping Substance Using the Same In force · High confidence | In force | High confidence | |
| US 11,066,459 | Hybrid immunoglobulin containing non-peptidyl linkage In force · USPTO record | In force | USPTO record | |
| US 11,220,556 | Hybrid immunoglobulin containing non-peptidyl linkage In force · USPTO record | In force | USPTO record |
Also on record, not counted in the 14: 2 lapsed for an unpaid fee · 1 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending · 1 abandoned · 5 no status recorded